Neuleptil (Periciazine)

Periciazine is used in the phenothiazine class to manage psychotic conditions by modulating dopamine pathways.

• Schizophrenia: reduces positive symptoms such as hallucinations and delusions, and improves overall mental stability.
• Acute psychotic disorders: helps control sudden onset psychotic episodes and stabilizes mood and perception.
• Schizoaffective disorder: alleviates psychotic features when present alongside mood symptoms.

• Periciazine exerts its antipsychotic effect primarily by blocking dopamine D2 receptors in the mesolimbic and mesocortical pathways, decreasing dopaminergic neurotransmission that underlies psychotic symptoms. It also exhibits antagonism at certain serotonin (5‑HT2) and histamine (H1) receptors, contributing to its therapeutic profile and side‑effect spectrum. The blockade reduces overactivity in the nigrostriatal pathway, which may lead to motor side effects, while the combined receptor activity influences sedation and prolactin levels.

Periciazine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Drowsiness: feeling of sleepiness or reduced alertness.
• Dry mouth: decreased salivation leading to discomfort.
• Constipation: slowed gastrointestinal motility.
• Blurred vision: temporary visual disturbances.
• Weight gain: increase in body weight over time.
• Orthostatic hypotension: dizziness upon standing.

Serious or Rare Side Effects

• Extrapyramidal symptoms: muscle rigidity, tremor, or involuntary movements.
• Tardive dyskinesia: persistent involuntary facial or limb movements.
• Neuroleptic malignant syndrome: life‑threatening fever, muscle rigidity, and autonomic instability.
• Seizures: occurrence of convulsive episodes.
• Agranulocytosis: severe reduction in white blood cells.
• Cardiac arrhythmias: irregular heart rhythms.

When prescribing Periciazine, clinicians should consider several safety precautions to minimize risks.

• Assess cardiovascular status: evaluate blood pressure and heart rhythm before initiating therapy.
• Monitor for extrapyramidal signs: observe patients for early movement disorders.
• Review metabolic profile: check weight, glucose, and lipid levels periodically.
• Caution in elderly: increased sensitivity to sedation and orthostatic hypotension.
• Avoid abrupt discontinuation: taper the dose to reduce withdrawal or relapse risk.
• Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Periciazine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• CNS depressants: concurrent use may enhance sedation and respiratory depression.
• Anticholinergic agents: may worsen cognitive impairment and increase anticholinergic burden.
• QT‑prolonging drugs: combined effect can raise the risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely)

• Dopamine agonists (e.g., levodopa): may reduce antipsychotic effectiveness.
• CYP2D6 inhibitors (e.g., fluoxetine): can increase Periciazine plasma levels.
• Antihypertensives: orthostatic hypotension may be amplified.
• Alcohol: additive central nervous system depression.